19-17843141-G-C
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BA1BS2_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_000215.4(JAK3):c.452C>G (p.Pro151Arg) variant in JAK3 is a missense variant predicted to cause the substitution of Proline by Arginine at amino acid 151 (p.Pro151Arg). The Popmax Filtering allele frequency (95% CI) of the variant is 0.008679 in gnomAD v.4 for European (non-Finnish) population 10486/1179548 alleles, which is higher than the ClinGen SCID VCEP threshold (>0.00447) for BA1, therefore, meets this criterion (BA1). Also, 59 homozygous adults are reported on GnomAD v2.1.1 (BS2_Supporting). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive T-B+ severe combined immunodeficiency due to JAK3 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1 and BS2_Supporting (VCEP specifications version 1.0). LINK:https://erepo.genome.network/evrepo/ui/classification/CA160252/MONDO:0010938/121
Frequency
Consequence
NM_000215.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
JAK3 | NM_000215.4 | c.452C>G | p.Pro151Arg | missense_variant | 5/24 | ENST00000458235.7 | |
JAK3 | XM_047438786.1 | c.452C>G | p.Pro151Arg | missense_variant | 5/24 | ||
JAK3 | XM_011527991.3 | c.452C>G | p.Pro151Arg | missense_variant | 5/14 | ||
JAK3 | XR_007066796.1 | n.502C>G | non_coding_transcript_exon_variant | 5/20 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
JAK3 | ENST00000458235.7 | c.452C>G | p.Pro151Arg | missense_variant | 5/24 | 5 | NM_000215.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00642 AC: 977AN: 152174Hom.: 7 Cov.: 32
GnomAD3 exomes AF: 0.00592 AC: 1400AN: 236668Hom.: 4 AF XY: 0.00626 AC XY: 817AN XY: 130472
GnomAD4 exome AF: 0.00791 AC: 11511AN: 1455712Hom.: 52 Cov.: 33 AF XY: 0.00782 AC XY: 5668AN XY: 724368
GnomAD4 genome AF: 0.00642 AC: 978AN: 152292Hom.: 7 Cov.: 32 AF XY: 0.00680 AC XY: 506AN XY: 74466
ClinVar
Submissions by phenotype
T-B+ severe combined immunodeficiency due to JAK3 deficiency Uncertain:1Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Benign, reviewed by expert panel | curation | ClinGen Severe Combined Immunodeficiency Variant Curation Expert Panel, ClinGen | Jan 23, 2024 | The NM_000215.4(JAK3):c.452C>G (p.Pro151Arg) variant in JAK3 is a missense variant predicted to cause the substitution of Proline by Arginine at amino acid 151 (p.Pro151Arg). The Popmax Filtering allele frequency (95% CI) of the variant is 0.008679 in gnomAD v.4 for European (non-Finnish) population 10486/1179548 alleles, which is higher than the ClinGen SCID VCEP threshold (>0.00447) for BA1, therefore, meets this criterion (BA1). Also, 59 homozygous adults are reported on GnomAD v2.1.1 (BS2_Supporting). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive T-B+ severe combined immunodeficiency due to JAK3 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1 and BS2_Supporting (VCEP specifications version 1.0). - |
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | GeneDx | Aug 16, 2018 | This variant is associated with the following publications: (PMID: 25333069, 21228398, 26248889, 27484032, 11668610, 24728327, 10982185, 27577878, 27151993, 27884173) - |
Benign, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | May 06, 2015 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2023 | JAK3: BP4, BS2 - |
not specified Benign:2Other:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 22, 2022 | Variant summary: JAK3 c.452C>G (p.Pro151Arg) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0061 in 269660 control chromosomes, predominantly at a frequency of 0.011 within the Non-Finnish European subpopulation in the gnomAD database, including five homozygotes. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 12 fold of the estimated maximal expected allele frequency for a pathogenic variant in JAK3 causing Severe Combined Immunodeficiency phenotype (0.00094), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.452C>G has been reported in the literature in at least one individual affected with Severe Combined Immunodeficiency (Schumacher_2000). The report does not provide unequivocal conclusions about association of the variant with Severe Combined Immunodeficiency. Five ClinVar submitters (evaluation after 2014) cite the variant as benign (n=4) and uncertain significance (n=1). Based on the evidence outlined above, the variant was classified as benign. - |
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 28, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Reported in 1 heterozygote individual with SCID (Schumacher 2000). 1.3% frequency. - |
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at